Profile data is unavailable for this security.
About the company
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
- Revenue in USD (TTM)72.12k
- Net income in USD-5.08m
- Incorporated2023
- Employees--
- LocationSilo Pharma Inc677 N Washington BlvdSARASOTA 34236United StatesUSA
- Websitehttps://silopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENDRA Life Sciences Inc | 0.00 | -8.01m | 4.49m | 21.00 | -- | 17.68 | -- | -- | -13.35 | -13.35 | 0.00 | 0.2178 | 0.00 | -- | -- | 0.00 | -154.83 | -132.71 | -183.46 | -155.93 | -- | -- | -- | -- | 1.31 | -- | 0.00 | -- | -- | -- | -14.39 | -- | -18.17 | -- |
| BioRestorative Therapies Inc | 383.40k | -12.67m | 4.50m | 11.00 | -- | 0.7578 | -- | 11.74 | -1.48 | -1.48 | 0.0447 | 0.2766 | 0.0379 | -- | 4.30 | 34,854.55 | -125.35 | -149.02 | -207.73 | -188.71 | 93.34 | -- | -3,304.77 | -11,837.37 | -- | -- | 0.00 | -- | 175.03 | 25.27 | 13.81 | -- | 24.41 | -- |
| Revelation Biosciences Inc | 0.00 | -14.87m | 4.58m | 8.00 | -- | 0.2199 | -- | -- | -62.09 | -62.09 | 0.00 | 5.59 | 0.00 | -- | -- | 0.00 | -97.93 | -135.98 | -124.73 | -249.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 1.15 | -- | -- | -- |
| Genprex Inc | 0.00 | -17.05m | 4.64m | 15.00 | -- | 2.62 | -- | -- | -52.85 | -52.85 | 0.00 | 0.7646 | 0.00 | -- | -- | 0.00 | -448.99 | -100.44 | -1,253.41 | -109.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.69 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 127.36k | -592.60k | 4.65m | 2.00 | -- | -- | -- | 36.52 | -0.00006 | -0.00006 | 0.00001 | -0.0001 | 4.48 | -- | 7.15 | 63,680.00 | -2,082.95 | -652.66 | -- | -- | 66.56 | 87.76 | -465.30 | -177.59 | -- | -4.27 | -- | -- | 21.77 | 0.8662 | 15.74 | -- | -- | -- |
| Bio Green Med Solution Inc | 81.00k | -6.97m | 4.70m | 12.00 | -- | 0.4734 | -- | 58.08 | -80.13 | -80.13 | 0.0775 | 2.03 | 0.012 | -- | 0.0821 | -- | -80.35 | -65.34 | -175.85 | -83.85 | 20.99 | -- | -6,714.82 | -17,774.73 | 5.07 | -241.39 | 0.00 | -- | -89.76 | -- | 50.73 | -- | -- | -- |
| Nymox Pharmaceutical Corp | -100.00bn | -100.00bn | 4.79m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -0.0717 | -- | -- | -- | -- | -- | -397.74 | -- | -- | -- | -- | -- | -883,740.00 | -- | -- | -- | -- | -- | -- | 49.21 | -- | -- | -- |
| MetaVia Inc | 0.00 | -16.22m | 5.00m | 9.00 | -- | 0.5424 | -- | -- | -13.88 | -13.88 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -87.87 | -99.54 | -167.49 | -140.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -121.27 | -- | -48.18 | -- |
| VivoSim Labs Inc | 142.00k | -1.23m | 5.01m | 5.00 | 1.80 | 1.13 | -- | 35.26 | 1.07 | 1.07 | 0.0608 | 1.70 | 0.0263 | -- | 4.81 | 10,923.08 | -22.71 | -51.63 | -45.51 | -56.47 | 100.00 | -- | -864.08 | -2,952.99 | -- | -- | 0.00 | -- | 32.11 | -42.01 | 83.04 | -- | -- | -- |
| Mosaic Immunoengineering Inc | 0.00 | -671.75k | 5.10m | 2.00 | -- | -- | -- | -- | -0.0928 | -0.0928 | 0.00 | -1.01 | 0.00 | -- | -- | 0.00 | -1,410.50 | -- | -- | -- | -- | -- | -- | -- | -- | -7.37 | -- | -- | -- | -- | 8.56 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -5.08m | 5.10m | -- | -- | 0.7999 | -- | 70.73 | -0.9262 | -0.9262 | 0.0117 | 0.4788 | 0.0097 | -- | -- | -- | -67.91 | -29.61 | -76.93 | -32.10 | 65.24 | 92.17 | -7,039.37 | -3,630.72 | -- | -- | 0.00 | -- | 0.00 | 12.19 | -20.98 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 2.86m | -2.20m | 5.30m | 1.00 | -- | 0.523 | -- | 1.86 | -0.7587 | -0.7587 | 1.00 | 2.58 | 0.2957 | -- | 39.65 | 2,855,000.00 | -22.77 | -53.70 | -24.80 | -63.57 | -- | -- | -77.02 | -1,913.83 | -- | -- | 0.00 | -- | -- | -15.00 | 75.72 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -56.98m | 5.30m | 36.00 | -- | 4.90 | -- | -- | -1.22 | -1.22 | 0.00 | 0.0194 | 0.00 | -- | -- | 0.00 | -48.20 | -42.95 | -55.60 | -46.33 | -- | -- | -- | -- | -- | -- | 0.943 | -- | -- | -- | -81.07 | -- | 36.12 | -- |
| Xenetic Biosciences Inc | 2.86m | -3.16m | 5.34m | 2.00 | -- | 0.9087 | -- | 1.87 | -2.05 | -2.05 | 1.85 | 2.57 | 0.436 | -- | -- | 1,429,470.00 | -48.14 | -42.99 | -57.42 | -46.44 | -- | -- | -110.40 | -373.71 | -- | -- | 0.00 | -- | -1.56 | 171.11 | 4.22 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -25.62m | 5.45m | 28.00 | -- | 0.7596 | -- | -- | -9.62 | -9.62 | 0.00 | 1.00 | 0.00 | -- | -- | 0.00 | -194.84 | -- | -1,279.90 | -- | -- | -- | -- | -- | -- | -58.24 | 0.1544 | -- | -- | -- | 18.49 | -- | -- | -- |
| Silexion Therapeutics Corp | 0.00 | -9.25m | 5.54m | 11.00 | -- | 0.7449 | -- | -- | -25.21 | -25.21 | 0.00 | 2.23 | 0.00 | -- | -- | 0.00 | -125.80 | -- | -221.96 | -- | -- | -- | -- | -- | -- | -84.50 | 0.1808 | -- | -- | -- | -223.39 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to Silo Pharma Inc's reporting currency: US Dollar USD
9.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AdvisorShares Investments LLCas of 31 Dec 2025 | 599.51k | 4.50% |
| DRW Securities LLCas of 31 Dec 2025 | 333.73k | 2.51% |
| Geode Capital Management LLCas of 31 Dec 2025 | 92.91k | 0.70% |
| XTX Markets LLCas of 31 Dec 2025 | 56.90k | 0.43% |
| Jane Street Capital LLCas of 31 Dec 2025 | 34.37k | 0.26% |
| G1 Execution Services LLCas of 31 Dec 2025 | 29.58k | 0.22% |
| Virtu Americas LLCas of 31 Dec 2025 | 18.42k | 0.14% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 13.10k | 0.10% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 12.50k | 0.09% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.22k | 0.08% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
